Increase in the size of the gingiva is a common feature of gingival disease. Accepted current terminology for this condition is gingival enlargement and gingival overgrowth. These are strictly clinical descriptive terms and avoid the erroneous pathologic connotations of terms used in the past such as hypertrophic gingivitis or gingival hyperplasia. The gingiva and associated soft tissues of the periodontium may be enlarged in response to various interactions between the host and the environment. Although such enlargement usually represents an inflammatory response to bacterial plaque, increased susceptibility as a result of systemic factors or conditions should always be considered during the course of patient evaluation. Systemically related gingival enlargements include, but are not limited to, scurvy, leukemia, puberty, pregnancy, multisystem syndromes and selected drugs and/or agents. In addition, fibrotic gingival enlargement has been reported and is believed to be the result of a genetic predisposition (for example hereditary or familial gingival enlargement). However an idiopathic variant that has not been associated with genetic linkage or cause has been described. Of the predisposing factors associated with the gingival enlargement, selected anticonvulsant drug, Calcium channel blockers and a potent immunosuppressant (Cyclosporine A) have generated the most investigative attention in the scientific community.
Since the first report of Phenytoin induced gingival overgrowth by Kimball in 1939, many clinical and investigative studies have been carried out to determine the pathogenesis of this disorder. Although these studies yielded various pathogenetic data, it is still unknown why drugs with such different pharmacological actions induce similar gingival changes. Furthermore different views concerning the interrelationships between blood drug levels and/or duration of drug intake and the severity of growth, sex predilection, effect of local inflammation and incidence has been reported in the literature.
The genetically determined capacity of the host to deal metabolically with chronically administered drugs; the responsiveness of gingival tissues to the drugs and the pre-existing gingival condition may differ among individuals.
Table of Contents
I. Inflammatory enlargement
A. Chronic
B. Acute
II. Drug-induced enlargement
III. Enlargement associated with systemic diseases
A. Conditioned enlargement
1. Pregnancy
2. Puberty
3. Vitamin C deficiency
4. Plasma cell gingivitis
5. Non specific conditioned enlargement (Granuloma pyogenicum)
B. Systemic diseases causing gingival enlargement
1. Leukemia
2. Granulomatous diseases (Wegeners granulomatosis, sarcoidosis and so on)
IV. Neoplastic enlargement (gingival tumors)
A. Benign tumors
B. Malignant tumors
V. False enlargement
Research Objectives and Core Themes
This work aims to investigate the complex pathogenesis of drug-induced gingival overgrowth, exploring the multifactorial nature of its development in patients undergoing pharmacological therapy with anticonvulsants, immunosuppressants, or calcium channel blockers. The central research focus is to understand how these diverse drugs interact with gingival fibroblasts, systemic factors, and local inflammation to produce similar clinical manifestations of tissue enlargement.
- Pathophysiological mechanisms of drug-gingival fibroblast interactions.
- Role of bacterial plaque and inflammatory response in lesion progression.
- Genetic and phenotypic heterogeneity in fibroblast responsiveness.
- Evaluation of clinical classification indices and indices of severity.
- Preventive strategies and management options for clinical practice.
Excerpt from the Book
Clinical Features
The growth starts as a painless beadlike enlargement of the interdental papillae and extends to the facial and lingual margins. As the condition progresses, the marginal and papillary enlargements unite; they may develop into a massive tissue fold covering a considerable portion of the crowns and they may interfere with occlusion. When uncomplicated by inflammation, the lesion is mulberry shaped, firm, pale pink and resilient, with a minutely lobulated surface and no tendency to bleed. The enlargement characteristically appears to project from beneath the gingival margin, from which it is separated by a linear groove.
The enlargement is usually generalized throughout the mouth but is more severe in the maxillary and mandibular anterior regions. It occurs in areas in which teeth are present, not in edentulous spaces and the enlargement disappears in areas from which teeth are extracted. Hyperplasia of the mucosa in edentulous mouth has been reported but is rare. The enlargement is chronic and slowly increases in size. When surgically removed it recurs. Spontaneous disappearance occurs within a few months after discontinuation of the drug.
Summary of Chapters
I. Inflammatory enlargement: Covers the classification of gingival tissue increases based on clinical pathology, differentiating between chronic and acute inflammatory responses.
II. Drug-induced enlargement: Discusses the overarching category of gingival overgrowth specifically associated with the administration of systemic medications.
III. Enlargement associated with systemic diseases: Details how various conditions, ranging from physiological changes like puberty to specific systemic pathologies, affect gingival tissue size.
IV. Neoplastic enlargement (gingival tumors): Addresses the classification of benign and malignant gingival tumors that present as tissue enlargements.
V. False enlargement: Defines the criteria for classifying gingival enlargements based on their specific location and distribution within the oral cavity.
Keywords
Gingival enlargement, Gingival overgrowth, Phenytoin, Cyclosporine A, Calcium channel blockers, Fibroblasts, Pathogenesis, Inflammation, Dental plaque, Collagenase, Pharmacokinetics, Hyperplasia, Oral hygiene, Periodontal surgery, Immunosuppressants
Frequently Asked Questions
What is the primary focus of this work?
The work focuses on the clinical characteristics, underlying pathogenic mechanisms, and management strategies for gingival enlargement caused by specific systemic medications.
Which medication classes are identified as triggers for this condition?
The primary drug classes identified are anticonvulsants (such as Phenytoin), immunosuppressants (such as Cyclosporine A), and various calcium channel blockers.
What is the central research question regarding pathogenesis?
The work explores why pharmacologically different drugs are capable of inducing remarkably similar clinical changes in gingival tissue, specifically focusing on fibroblast heterogeneity and collagenase activation.
Which scientific methods are primarily utilized?
The study relies on a comprehensive literature review of clinical case reports, in-vitro fibroblast culture studies, and experimental models, including rat models of drug-induced overgrowth.
What does the main body of the work cover?
The main body examines detailed hypotheses regarding drug interactions with gingival tissue, the role of plaque-induced inflammation, histological characteristics, and clinical management through preventive programs and surgical intervention.
Which keywords best characterize this research?
Key terms include gingival overgrowth, pharmacological side effects, fibroblast heterogeneity, collagen metabolism, and plaque control.
Why is the "New clinical index for gingival overgrowth" significant?
This index is significant because it provides a standardized, multi-dimensional way to assess and compare the severity of lesions across different patient populations, aiding in treatment planning.
How does the author propose managing these lesions?
The author proposes a stepwise approach: drug substitution if possible, rigorous plaque control, and, if those fail to prevent or resolve the condition, surgical intervention like gingivectomy or flap surgery.
- Arbeit zitieren
- Dr. Rajesh Hosadurga (Autor:in), 2005, Drug Induced Gingival Enlargement, München, GRIN Verlag, https://www.grin.com/document/215797
